Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
GlobeNewswire
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024
Initiation of Pivotal..
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024
Initiation of Pivotal..
COVID-19 vaccines that have been proven to prevent long-term illness, hospitalization and death were linked to small increases in..
ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024; Potential to be First Approved..